LCGC Application Note Alert Having trouble viewing this email? Click here UHPLC analysis of challenging MAbs This application note using YMC-Triart Bio C4 shows a robust separation at high temperatures of 3 commercially available MAbs: Ofatumumab, Palivizumab, and Panitumumab. Analysing Bevacizumab, its aggregates and fragments The dedicated SEC column for antibodies, YMC-SEC MAB, is used to separate the MAb monomer from its aggregates as well as from degradation products in a single run. Commercial MAbs by Micro-LC–MS/MS YMC-Triart Bio C4 is used in YMC capillary column format to analyse and identify intact commercial MAbs by micro-LC- MS/MS at an elevated temperature of 75°C. Analysis of intact proteins by Micro-LC–MS/MS In this application note eight intact proteins in the protein mix MSRT2 are analysed by Micro-LC–MS using an YMC-Triart Bio C4 capillary column. LC–MS compatible ADC analysis by reverse-phase In this application YMC-Triart Bio C4 was used to analyse a reduced monoclonal antibody and a reduced ADC mimic with formic acid or TFA as additives. High throughput DAR determination of Brentuximab vedotin YMC’s latest HIC column is used to analyse the DAR of Brentuximab vedotin allowing higher flow rates and shorter run times thanks to the pressure resistant particle. Reverse-phase separation of disulfide modified oligonucleotides The less hydrophobic wide-pore column YMC-Triart Bio C4 is used for the analysis of modified oligonucleotides due to the hydrophobic character of the disulfide units. Optimisation of phosphorothioate oligonucleotide AEX separation This application note shows how to achieve narrow peaks and high sensitivity by optimising the AEX separation of phosphorothioate oligonucleotides (PS) in only 5 steps.